English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/138990
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorCorvillo, Fernandoes_ES
dc.contributor.authorMaría Bravo García-Moratoes_ES
dc.contributor.authorNozal, Pilares_ES
dc.contributor.authorGarrido, Sofíaes_ES
dc.contributor.authorTortajada, Agustínes_ES
dc.contributor.authorRodríguez de Córdoba, Santiagoes_ES
dc.contributor.authorLópez-Trascasa, Margaritaes_ES
dc.identifier.citationClin Exp Immunol. 184(1):118-25 (2016)es_ES
dc.description24 p.-3 fig.-3 tab.es_ES
dc.description.abstractProperdin (P) stabilizes the alternative pathway (AP) convertases, being the only known positive regulator of complement system. In addition, P is a pattern recognition molecule able to initiate directly the AP on non-self surfaces. Although P deficiencies are long time known to be associated with Neisseria infections and P is often found deposited at sites of AP activation and tissue injury, the potential role of P in the pathogenesis of complement dysregulation associated disorders has not been extensively studied. Serum P levels were measured in 49 patients with histological and clinical evidence of C3 glomerulopathy (C3G). Patients were divided in two groups according to the presence or absence of C3 nephritic factor (C3NeF), an autoantibody that stabilizes the AP C3 convertase. The presence of this autoantibody results in a significant reduction in circulating C3 (p<0.001) and C5 levels (p<0.05), but does not alter factor B, P and sC5b-9 levels. Interestingly, in our cohort, serum P levels were low in 17 of the 32 C3NeF-negative patients. This group exhibited significant reduction of C3 (p<0.001) and C5 (p<0.001), and increase of sC5b-9 (p<0.001) plasma levels, compared to the control group. Besides, P consumption was significantly correlated with C3 (r= 0.798, p 0.0001), C5 (r= 0.806, p<0.0001), sC5b-9 (r = -0.683, p 0.043) and a higher degree of proteinuria (r= -0.862, p 0.013). These results further illustrate the heterogeneity among C3G patients and suggest that P serum levels could be a reliable clinical biomarker to identify patients with underlying surface AP C5 convertase dysregulation.es_ES
dc.description.sponsorshipThis work was performed with the support of grants from the Spanish Ministerio de Economía y Competitividad (SAF2012-38636), Comunidad de Madrid (S2010/BMD-2316) and CIBERER (ACCI-2014).es_ES
dc.publisherJohn Wiley & Sonses_ES
dc.subjectAlternative pathwayes_ES
dc.subjectC3 nephritic factores_ES
dc.subjectC3 glomerulopathyes_ES
dc.subjectC3 glomerulonephritises_ES
dc.titleSerum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathyes_ES
dc.title.alternativeProperdin in C3 glomerulopathyes_ES
dc.description.peerreviewedPeer reviewedes_ES
dc.relation.publisherversionhttp://dx.doi.org/ 10.1111/cei.12754es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)es_ES
dc.contributor.funderComunidad de Madrides_ES
oprm.item.hasRevisionno ko 0 false*
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
serum_properdin_Corvillo.pdf4,26 MBAdobe PDFThumbnail
Show simple item record

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.